Terrance P. Coyne sold $10M of RPRX
EVP & CFO at Royalty Pharma plc. 243,541 shares at an average of $42.54, traded Feb 2, 2026, filed Feb 4, 2026.
Score components
- +22RoleCFO
- +25Trade size$10.4M at market
- +20Share of holdings soldSold 62% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001814876-26-000006, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 2, 2026 | SOpen-market sale Class A Ordinary Sharesindirect: By TPC RP 2021, LLC10b5-1 | -102,581 | $42.08 | $4.3M | 292,415 | Feb 4, 2026 |
| Feb 3, 2026 | SOpen-market sale Class A Ordinary Sharesindirect: By TPC RP 2021, LLC10b5-1 | -108,759 | $42.84 | $4.7M | 183,656 | Feb 4, 2026 |
| Feb 4, 2026 | SOpen-market sale Class A Ordinary Sharesindirect: By TPC RP 2021, LLC10b5-1 | -19,076 | $43.29 | $826k | 164,580 | Feb 4, 2026 |
| Feb 2, 2026 | SOpen-market sale Class A Ordinary Sharesindirect: TPC RP EPA1 LLC10b5-1 | -5,843 | $42.08 | $246k | 30,167 | Feb 4, 2026 |
| Feb 3, 2026 | SOpen-market sale Class A Ordinary Sharesindirect: TPC RP EPA1 LLC10b5-1 | -6,195 | $42.84 | $265k | 23,972 | Feb 4, 2026 |
| Feb 4, 2026 | SOpen-market sale Class A Ordinary Sharesindirect: TPC RP EPA1 LLC10b5-1 | -1,087 | $43.29 | $47k | 22,885 | Feb 4, 2026 |
Related signals
Other insiders at Royalty Pharma plc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | Royalty Pharma plc | Marshall Urist EVP, Research & Investments | $236k 4,126 shares | -100% | |
| 36Weak | Royalty Pharma plc | Marshall Urist EVP, Research & Investments | $239k 4,126 shares | -50% | |
| 43Moderate | Royalty Pharma plc | Christopher Hite EVP & Chairman, Partnering | $5.9M 100,000 shares | -27% | |
| 37Weak | Royalty Pharma plc | Terrance P. Coyne EVP & CFO | $1.6M 34,791 shares | -35% | |
| 37Weak | Royalty Pharma plc | Terrance P. Coyne EVP & CFO | $1.6M 34,791 shares | -26% | |
| 32Weak | Royalty Pharma plc | Terrance P. Coyne EVP & CFO | $1.6M 34,791 shares | -21% | |
| 32Weak | Royalty Pharma plc | Terrance P. Coyne EVP & CFO | $2.7M 69,582 shares | -15% | |
| 40Moderate | Royalty Pharma plc | Terrance P. Coyne EVP & CFO | $2.7M 69,582 shares | -13% | |
| 37Weak | Royalty Pharma plc | Marshall Urist EVP, Research & Investments | $786k 20,000 shares | -17% | |
| 37Weak | Royalty Pharma plc | Marshall Urist EVP, Research & Investments | $768k 20,000 shares | -14% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.